HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
Press releases
March 10, 2022
GelMEDIX
This partnership represents the first equity investment of the incubator created by HTL to accelerate the development of innovative treatments using biopolymers in therapeutic areas with unmet medical needs.
HTL will provide financial, industrial and scientific support to GelMEDIX to facilitate the development of next generation ocular and regenerative therapies based on its proprietary hydrogel platform.
This platform enables the delivery of therapeutics from small molecules to cell and gene therapies.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Press releases November 13, 2026HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
-
Articles October 30, 20262026 Regenerative Science Summit
HTL Biotechnology hosted a scientific summit in Chengdu, China, dedicated to PDRN/PN, bringing together more than 130 experts and professionals to discuss the latest scientific advances, regulatory developments and emerging applications.
-
Articles September 8, 2026HTL Biotechnology releases its 2025 CSR Report
Driven by the collective commitment of our teams, this report confirms the maturity of an internationally recognized approach, which was recognized this year with the EcoVadis Platinum medal, placing HTL Biotechnology among the top 1% of the world’s most committed companies.